Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
It is widely recognized that prostate cancer is a multifaceted illness that is the second most common cause of cancer-related fatalities among males. Natural sources from both plants and marine organisms have long been used in treating various diseases and in the discovery of new pharmaceutical compounds. Medicinal plants, in particular, provide bioactive substances like alkaloids, phenolic compounds, terpenes, and steroids. In addition, marine natural products play a crucial role in the search for novel cancer treatments. A substantial number of anticancer drugs have been derived from natural sources, including plants, marine organisms, and microorganisms. In fact, over the past 60 years, 80% of new chemical entities have originated from natural sources, which are generally considered safer than synthetic compounds. This review seeks to emphasize the role of phytochemical compounds derived from both plant and marine sources in prostate cancer, highlighting their potential therapeutic impact. It is also intended to support global researchers working on the identification of natural-based treatments for prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946378 | PMC |
| http://dx.doi.org/10.3390/ph18030286 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[PARP inhibitors (poly-ADP-ribose polymerase) : newcomers in the management of prostate cancers].
Rev Med Liege
September 2025
Service d'Oncologie Médicale, CHU Liège, Belgique.
This review aims to describe the role of poly-ADP-ribose polymerase inhibitors (PARPi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC), an aggressive and lethal form of the disease. The introduction of PARPi has led to improved prognosis, particularly in patients with at least one somatic or germline mutation in DNA damage repair genes such as BRCA1 or BRCA2. Several recent studies have shown that PARPi, used alone or in combination with abiraterone or enzalutamide, improve progression-free survival and overall survival in patients with mCRPC.
View Article and Find Full Text PDFUltrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives.
Clin Transl Oncol
September 2025
Department of Radiation Oncology, Vithas La Milagrosa University Hospital, Madrid, 28010, Spain.
This narrative review analyzes current evidence comparing single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy for localized prostate cancer. These ultra-hypofractionated strategies deliver high-precision ablative doses while minimizing exposure to normal tissues. SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience.
View Article and Find Full Text PDFAlgorithm to detect ISUP ≥ 2 prostate cancer using canine detection.
World J Urol
September 2025
Bichat Claude Bernard Hospital, Public Assistance of Paris Hospitals, Paris, France.
Purpose: Screening and diagnosing ISUP ≥ 2 prostate cancer is challenging. This study aimed to determine whether canine detection could be beneficial addition to the ISUP ≥ 2 prostate cancer diagnostic protocol by creating a decision-making algorithm for men with suspected prostate cancer.
Methods: We conducted a prospective study at two urology institutions and a French veterinary school, including men with a suspicion of prostate cancer from November to April 2023, which were divided into two groups according to their prostate biopsy results.
Outcomes of the management of synchronous rectal and prostate cancer: a systematic review.
Int J Colorectal Dis
September 2025
University of Aberdeen, Aberdeen, AB24 2ZD, Scotland, UK.
Background: The optimal management of synchronous rectal cancer (RC) and prostate cancer (PC) remains unclear. This systematic review evaluates treatment strategies and reports postoperative, oncological, and quality-of-life outcomes in patients treated with curative intent.
Methods: Following PRISMA guidelines, this systematic review was registered in PROSPERO (CRD42024598049).
Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis.
Nature
September 2025
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Neural activity is increasingly recognized as a crucial regulator of cancer growth. In the brain, neuronal activity robustly influences glioma growth through paracrine mechanisms and by electrochemical integration of malignant cells into neural circuitry via neuron-to-glioma synapses. Outside of the central nervous system, innervation of tumours such as prostate, head and neck, breast, pancreatic, and gastrointestinal cancers by peripheral nerves similarly regulates cancer progression.
View Article and Find Full Text PDF